Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 18/20 | 0.53 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.46 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.46 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.43 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2748525 | 0.91 | MET (0.53) | METFGFR1FGFR2FGFR3KCNH2 | |
| SCHEMBL2748064 | 0.91 | MET (0.53) | METFGFR1FGFR2FGFR3KCNH2 | |
| SCHEMBL2749952 | 0.89 | MET (0.51) | METFGFR1FGFR2FGFR3KCNH2 | |
| SCHEMBL2751555 | 0.89 | MET (0.51) | METFGFR1FGFR2FGFR3KCNH2 | |
| SCHEMBL2749346 | 0.88 | MET (0.58) | METKCNH2PIK3CDKDRPIK3CA | |
| SCHEMBL2748451 | 0.88 | MET (0.56) | METFGFR1FGFR2FGFR3KCNH2 | |
| SCHEMBL2749930 | 0.88 | MET (0.56) | METFGFR1FGFR2FGFR3KCNH2 | |
| Hydrochloric Acid SCHEMBL2747210 | 0.88 | MET (0.59) | METKCNH2PIK3CDKDRPIK3CA | |
| SCHEMBL2749951 | 0.87 | MET (0.55) | METFGFR1FGFR2FGFR3KCNH2 | |
| SCHEMBL2749716 | 0.87 | MET (0.53) | METFGFR1FGFR2FGFR3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178668-B2 | 2-aminopyridine kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2012-05-15 | — | — | US | disclosed |
| US-20090197862-A1 | 2-AMINOPYRIDINE KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197862-A1 | 2-AMINOPYRIDINE KINASE INHIBITORS | ERBB2, ABL2, TIE1 | MET 38/4885FGFR1 15/4885FGFR2 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.